Functional expression, purification, and antimicrobial activity of a novel antimicrobial peptide MLH in Escherichia coli

Preparative Biochemistry & Biotechnology
Guo-Li GongZhong-Zhong Wang

Abstract

In this study, a novel heterozygous antimicrobial peptide MLH was synthesized, expressed, purified, and characterized. The peptide Md-cec-LL-37_Hp (MLH) was selected through bioinformatic analysis using musca domestica antimicrobial peptide (Cec-Med), human antimicrobial peptide LL-37, and helicobacter pylori antimicrobial peptide (Hp) as parent peptides. The target gene was synthesized by overlap extension PCR (SOE-PCR) and connected to the expression vector pET-32a (+), and the recombinant plasmid pET-32a-MLH was transformed to Escherichia coli for constructing pET-32a-MLH/BL21 (DE3). Isopropyl β-D-thiogalactoside (IPTG) was used to induce protein expression, and SDS-PAGE and western blot were adopted to test the target protein. And fermentation condition was optimized to get the mass expression of the fusion protein. The Ni2+affinity chromatographic column was used to purify. Active heterozygous peptide was obtained after renaturation. Finally, the activity of the heterozygous antimicrobial peptide was identified. The fusion peptide showed significant antimicrobial effect on both E. coli and Staphylococcus aureus.

References

May 5, 1999·Nature·K PütsepS Normark
May 4, 2002·Pharmaceutical Biotechnology·John F CarpenterTheodore W Randolph
Oct 9, 2002·Molecular Microbiology·Artur SchmidtchenLars Björck
Feb 18, 2004·Applied Microbiology and Biotechnology·J H Choi, S Y Lee
Nov 24, 2004·International Journal of Antimicrobial Agents·K V R ReddyC Aranha
Feb 11, 2005·Nature Reviews. Microbiology·Kim A Brogden
Jun 7, 2005·Protein Expression and Purification·Brian C BryksaNeil R Mattatall
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Joanne E ThwaiteTimothy P Atkins
Jul 19, 2006·Clinical Microbiology Reviews·Håvard JenssenRobert E W Hancock
Aug 22, 2006·Current Pharmaceutical Biotechnology·H Anne Pereira
Dec 5, 2008·FEMS Microbiology Letters·Yifeng Li, Zhengxin Chen
May 18, 2011·Cellular and Molecular Life Sciences : CMLS·Maria Luisa Mangoni
Jan 13, 2012·Current Pharmaceutical Design·Nicole J AfacanRobert E W Hancock
Jan 19, 2012·Current Pharmaceutical Biotechnology·Loredana Frasca, Roberto Lande
Apr 11, 2015·Evolutionary Applications·Alex R HallMartin Ackermann

❮ Previous
Next ❯

Methods Mentioned

BETA
protein assay
electrophoresis
PCR

Software Mentioned

Quantity One
ProtParam

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.